SR One is the corporate venture capital arm of GlaxoSmithKline.
Business Model:
Revenue: $11.4M
Employees: 2-10
Address: 1 Broadway
City: Cambridge
State: MA
Zip: 02142
Country: US
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.
Contact Phone:
+16105671000
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
7/2012 | Akamis Bio | Series B | 34.1M |
3/2017 | Spero Therapeutics | Series C | 51.7M |
11/2013 | Aileron Therapeutics | Series E | 30M |
1/2015 | Nkarta Therapeutics | Series A | 11M |
7/2020 | MISSION Therapeutics | Venture Round | 15M |
6/2014 | True North Therapeutics | Series A | 22M |
7/2007 | CalciMedica | Series A | 1.5M |
2/2009 | Genocea Biosciences | Series A | 23M |
11/2020 | F-Star Therapeutics | Post-IPO Equity | 0 |
10/2015 | Puridify | Series A | 3.4M |
3/2003 | Alere | Venture Round | 5.1M |
10/2022 | Odyssey Therapeutics | Series B | 0 |
12/2009 | CalciMedica | Series C | 12M |
10/2016 | Bicycle Therapeutics | Series A | - |
11/1999 | Physician Verification Services | Venture Round | - |
4/2016 | Second Genome | Series B | 51M |
2/2002 | Nucleonics | Series A | 1.6M |
1/2009 | 7TM Pharma | Venture Round | 0 |
1/2002 | Gryphon Therapeutics | Series B | 26M |
6/2011 | Nimbus Therapeutics | Series A | 24M |
6/2010 | Constellation Pharmaceuticals | Series B | 22.3M |
6/2011 | Constellation Pharmaceuticals | Series B | 15M |
10/2018 | Gotham Therapeutics | Series A | 54M |
1/2005 | Predix Pharmaceuticals | Series C | 0 |
10/2015 | Decibel Therapeutics | Series A | 52M |
6/2007 | 7TM Pharma | Series D | 22M |
10/2007 | Altiris Therapeutics | Series B | 0 |
1/2021 | River 2 Renal | Series A | 40M |
12/2014 | Avhana Health | Seed Round | 0 |
3/2005 | Novalar Pharmaceuticals | Series C | 27M |
1/2005 | OctoPlus | Series B | 23.9M |
6/2022 | Ancora Biotech LLC | Series A | 60M |
10/2019 | MiroBio | Series A | 33.2M |
1/1999 | Lexicon Pharmaceuticals | Post-IPO Equity | 0 |
2/2016 | Spero Therapeutics | Series B | 30M |
5/2020 | HotSpot Therapeutics | Series B | 65M |
6/2022 | MiroBio | Series B | 0 |
5/2021 | Pulmocide | Series C | 0 |
3/2017 | Pulmocide | Series B | 30.4M |
3/2015 | Zikani Therapeutics | Series A | 22M |
8/2015 | Principia Biopharma | Series B | 15.3M |
1/2018 | Pandion Therapeutics | Series A | 58M |
7/2014 | Atox Bio | Series E | 23M |
12/2021 | Odyssey Therapeutics | Series A | 0 |
11/2020 | Decibel Therapeutics | Series D | 82.2M |
4/2014 | Principia Biopharma | Series B | 50M |
6/2015 | Spero Therapeutics | Series A | 0 |
1/2012 | Translate Bio | Series A | 20.7M |
5/1999 | Xenogen Corporation | Series D | 11M |
5/2013 | Effector Therapeutics | Series A | 45M |
5/2017 | Turning Point Therapeutics | Series C | 45M |
11/2007 | Novalar Pharmaceuticals | Series D | 30M |
6/2006 | Melinta Therapeutics | Series C | 0 |
5/2014 | Puridify | Seed Round | 1.4M |
2/2016 | MISSION Therapeutics | Series C | 86.5M |
5/2015 | Akamis Bio | Series C | 38.8M |
4/2014 | Spero Therapeutics | Series A | 0 |
12/2013 | VHSquared | Series A | - |
11/2010 | Syntaxin | Series C | 29M |
4/2014 | Alios BioPharma | Series B | 41M |
11/2000 | Onyvax | Venture Round | 14.9M |
12/1997 | Onyvax | Venture Round | - |
5/2006 | Onyvax | Series C | 14.9M |
9/2022 | Nimbus Therapeutics | Venture Round | 0 |
12/2021 | Nomic Bio | Series A | 17M |
1/2009 | CalciMedica | Series C | 4M |
1/2022 | Simcha Therapeutics | Series B | 40M |
8/2016 | Tioma Therapeutics | Series A | 86M |
11/2003 | Protein Forest | Series A | 19M |
12/2017 | Atox Bio | Series F | 0 |
2/2007 | Locus Pharmaceuticals | Series E | 30.2M |
1/2002 | Melinta Therapeutics | Series A | 22M |
5/2018 | Propeller Health | Series D | 20M |
8/2005 | Protez Pharmaceuticals | Series B | 15M |
6/2022 | Mineralys Therapeutics | Series B | 0 |
12/2003 | Linguagen | Series A | 2M |
4/2015 | ZappRx | Series A | 14M |
1/1999 | Message Pharmaceuticals | Venture Round | 6.3M |
7/2015 | Translate Bio | Series B | 0 |
4/2011 | F-Star Therapeutics | Venture Round | 0 |
3/2020 | Design Therapeutics | Series A | 45.5M |
6/2014 | Navitor Pharmaceuticals | Series A | 23.5M |
10/2016 | Propeller Health | Series C | 21.5M |
4/2015 | True North Therapeutics | Series B | 35M |
1/2008 | POINT Biomedical | Private Equity Round | 0 |
10/2019 | Arcellx | Series B | 0 |
9/2006 | Addex Therapeutics | Series C | 0 |
10/2007 | Syntaxin | Series B | 32M |
12/2012 | Bicycle Therapeutics | Venture Round | 6M |
9/2003 | Conforma Therapeutics | Series C | 30M |
10/2012 | Principia Biopharma | Series A | 12.5M |
4/2020 | Pandion Therapeutics | Series B | 80M |
6/2009 | Aileron Therapeutics | Series D | 40M |
11/2012 | Applied Genetics Technologies Corporation | Series B | 0 |
6/2018 | Decibel Therapeutics | Series C | 55M |
9/2020 | Palleon Pharmaceuticals | Series B | 100M |
1/2009 | Melinta Therapeutics | Series D | 0 |
6/2004 | Nucleonics | Series B | 49.2M |
9/2019 | Nkarta Therapeutics | Series B | 114M |
9/2012 | IlluminOss Medical | Series C | 0 |
10/2013 | F-Star Therapeutics | Series A | 0 |
10/2014 | Atopix Therapeutics | Series A | 0 |
9/2007 | Novalar Pharmaceuticals | Series D | 30M |
1/2017 | Translate Bio | Series C | 51M |
2/2002 | Avantium | Venture Round | 0 |
10/2001 | Therion Biologics | Venture Round | 0 |
9/2021 | ADARx Pharmaceuticals | Series B | 75M |
9/2003 | Therion Biologics | Venture Round | 0 |
5/2000 | Xenogen Corporation | Series E | 30.6M |
10/2006 | Morphotek | Series D | 0 |
12/2010 | Semprus BioSciences | Series B | 18M |
9/2005 | Algeta | Series A | 28.9M |
6/2015 | Gladius Pharmaceuticals | Series A | 3.3M |
3/2015 | Thrasos | Series D | 21M |
10/2012 | Thrasos | Series C | 35M |
10/2014 | Aileron Therapeutics | Series E | 33M |
10/2012 | Genocea Biosciences | Series C | 30M |
12/2009 | Genocea Biosciences | Series B | 25.7M |
7/2013 | Dicerna Pharmaceuticals | Series C | 0 |
11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
10/2014 | Bicycle Therapeutics | Series A | 32M |
12/2012 | River Vision Development | Series A | 17M |
5/2021 | BioTheryX | Series E | 92M |
10/2016 | True North Therapeutics | Series D | 45M |
1/2014 | ZappRx | Seed Round | 1M |
10/2020 | Dren Bio | Series A | 0 |
5/2009 | Bird Rock Bio | Series A | 13M |
6/2018 | Nimbus Therapeutics | Series B | 65M |
6/2017 | Bicycle Therapeutics | Series B | 52M |
10/2017 | Palleon Pharmaceuticals | Series A | 47.6M |
8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
9/2018 | Morphic Therapeutic | Series B | 0 |
1/2011 | Genocea Biosciences | Series B | 35M |
12/2015 | Navitor Pharmaceuticals | Series B | 33M |
12/2015 | Effector Therapeutics | Series B | 40M |
4/2015 | CRISPR Therapeutics | Series A | 35M |
4/2015 | CRISPR Therapeutics | Series B | 29M |
12/2005 | Hypnion | Series B | 0 |
7/2017 | Effector Therapeutics | Series C | 38.6M |
8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
7/2011 | HTG Molecular Diagnostics | Series D | 0 |
9/2020 | Fore Biotherapeutics | Series C | 57M |
5/2010 | Ntprx | Series B | 43M |
11/2010 | iPierian | Series B | 29M |
7/2016 | Progyny | Series B | 14.7M |
5/2017 | Progyny | Series B | 10M |
9/2013 | iPierian | Venture Round | 30M |
12/2015 | True North Therapeutics | Series C | 40M |
1/2021 | Design Therapeutics | Series B | 125M |
8/2021 | ARS Pharmaceuticals | Series D | 55M |
4/2018 | Constellation Pharmaceuticals | Series F | 0 |
1/2023 | ADARx Pharmaceuticals | Series B | 0 |
10/2018 | Turning Point Therapeutics | Equity | 80M |
11/2022 | Rezo | Series A | 0 |
11/2021 | HotSpot Therapeutics | Series C | 0 |
11/2013 | MISSION Therapeutics | Series B | 32.2M |
8/2011 | MISSION Therapeutics | Series A | 6M |
1/2021 | River 3 Renal | Series A | 40M |
12/2022 | Pulmocide | Series C | 0 |
3/2015 | Nimbus Therapeutics | Series B | 43M |
11/2006 | PharmaKodex | Series A | 13.5M |
6/2009 | Anaphore | Series A | 13M |
4/2018 | Zikani Therapeutics | Venture Round | 0 |
9/2015 | Asceneuron | Series A | 30.8M |
4/2010 | Bicycle Therapeutics | Seed Round | - |
7/2008 | NuPathe | Series B | 30M |
8/1998 | MicroMass Communications | Venture Round | 7M |
6/2022 | Dren Bio | Series B | 0 |
3/2014 | Bird Rock Bio | Series B | 0 |
7/2020 | Tranquis Therapeutics | Series A | 30M |
6/2016 | Morphic Therapeutic | Series A | 0 |
8/2006 | Ablynx | Series C | 50M |
3/2003 | Hypnion | Series B | 47.5M |
10/2010 | Dicerna Pharmaceuticals | Series B | 4M |
1/2013 | Aileron Therapeutics | Series D | 12M |
4/2017 | ZappRx | Series B | 25M |
6/2022 | MiroBio | Series B | 0 |
6/2022 | Ancora Biotech LLC | Series A | 0 |
6/2022 | Dren Bio | Series B | 0 |
6/2022 | Mineralys Therapeutics | Series B | 0 |
1/2022 | Simcha Therapeutics | Series B | 0 |
12/2021 | nplex biosciences | Series A | 0 |
12/2021 | Odyssey Therapeutics | Series A | 0 |
11/2021 | HotSpot Therapeutics | Series C | 0 |
9/2021 | ADARx Pharmaceuticals | Series B | 0 |
8/2021 | ARS Pharmaceuticals | Series D | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|